ImmunoPrecise grew 475% during the period.
The pre-clinical trial will examine the safety, tolerability and efficacy of the proposed therapeutic cocktail in the SARS-CoV-2, Syrian hamster model.
DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.
Thee number of issued and outstanding Common Shares being reduced from 83,809,015 to 16,761,803.
A copy of the Preliminary Shelf Prospectus can be found under the Company’s SEDAR profile at www.sedar.com and on EDGAR at www.sec.gov.
The Nasdaq listing will enable the Company to gain increased liquidity and trading volume and broaden the Company’s investor base.